The determinants of tumour immunogenicity

被引：329

作者：

Blankenstein, Thomas ^{[1
,2
]}

Coulie, Pierre G. ^{[3
]}

Gilboa, Eli ^{[4
]}

Jaffee, Elizabeth M. ^{[5
]}

机构：

[1] Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany

[2] Charite, Inst Immunol, D-12200 Berlin, Germany

[3] Catholic Univ Louvain, de Duve Inst, B-1200 Brussels, Belgium

[4] Univ Miami, Miller Sch Med, Dodson Interdisciplinary Immunotherapy Inst, Dept Microbiol & Immunol, Miami, FL 33134 USA

[5] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21231 USA

来源：

NATURE REVIEWS CANCER | 2012年 / 12卷 / 04期

关键词：

REGULATORY T-CELLS; IMMUNE RESISTANCE; CANCER IMMUNOSURVEILLANCE; PANCREATIC-CANCER; HUMAN-MELANOMA; CLASS-I; IMMUNOTHERAPY; LYMPHOCYTES; DESTRUCTION; RECEPTOR;

D O I：

10.1038/nrc3246

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Many standard and targeted therapies, as well as radiotherapy, have been shown to induce an anti-tumour immune response, and immunotherapies rely on modulating the host immune system to induce an anti-tumour immune response. However, the immune response to such therapies is often reliant on the immunogenicity of a tumour. Tumour immunogenicity varies greatly between cancers of the same type in different individuals and between different types of cancer. So, what do we know about tumour immunogenicity and how might we therapeutically improve tumour immunogenicity? We asked four leading cancer immunologists around the world for their opinions on this important issue.

引用

页码：307 / 313

页数：7

共 68 条

[1] BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.iy.12.040194.002005
[2] Human T cell responses against melanoma
Boon, Thierry
Coulie, Pierre G.
Van den Eynde, Benoit J.
van der Bruggen, Pierre
[J]. ANNUAL REVIEW OF IMMUNOLOGY, 2006, 24 : 175 - 208
[3] Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
Buckanovich, Ronald J.
Facciabene, Andrea
Kim, Sarah
Benencia, Fabian
Sasaroli, Dimitra
Balint, Klara
Katsaros, Dionysios
O'Brien-Jenkins, Anne
Gimotty, Phyllis A.
Coukos, George
[J]. NATURE MEDICINE, 2008, 14 (01) : 28 - 36
[4] BURNET FM, 1964, BRIT MED B, V20, P154
[5] Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N
Pequignot, MO
Tesniere, A
Ghiringhelli, F
Roux, S
Chaput, N
Schmitt, E
Hamai, A
Hervas-Stubbs, S
Obeid, M
Coutant, F
Métivier, D
Pichard, E
Aucouturier, P
Pierron, G
Garrido, C
Zitvogel, L
Kroemer, G
[J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (12) : 1691 - 1701
[6] The immune system: a weapon of mass destruction invented by evolution to even the odds during the war of the DNAs
Cohn, M
[J]. IMMUNOLOGICAL REVIEWS, 2002, 185 : 24 - 38
[7] Antigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases
Corbiere, Veronique
Chapiro, Jacques
Stroobant, Vincent
Ma, Wenbin
Lurquin, Christophe
Lethe, Bernard
van Baren, Nicolas
Van den Eynde, Benoit J.
Boon, Thierry
Coulie, Pierre G.
[J]. CANCER RESEARCH, 2011, 71 (04) : 1253 - 1262
[8] Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
Curiel, TJ
Coukos, G
Zou, LH
Alvarez, X
Cheng, P
Mottram, P
Evdemon-Hogan, M
Conejo-Garcia, JR
Zhang, L
Burow, M
Zhu, Y
Wei, S
Kryczek, I
Daniel, B
Gordon, A
Myers, L
Lackner, A
Disis, ML
Knutson, KL
Chen, LP
Zou, WP
[J]. NATURE MEDICINE, 2004, 10 (09) : 942 - 949
[9] A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and CD8 Tumor-Infiltrating Lymphocytes and Favors Tumor Rejection in Mice
Demotte, Nathalie
Wieers, Gregoire
Van der Smissen, Patrick
Moser, Muriel
Schmidt, Christopher
Thielemans, Kris
Squifflet, Jean-Luc
Weynand, Birgit
Carrasco, Javier
Lurquin, Christophe
Courtoy, Pierre J.
van der Bruggen, Pierre
[J]. CANCER RESEARCH, 2010, 70 (19) : 7476 - 7488
[10] Mechanisms of immune evasion by tumors
Drake, CG
Jaffee, E
Pardoll, DM
[J]. ADVANCES IN IMMUNOLOGY, VOL 90: CANCER IMMUNOTHERAPY, 2006, 90 : 51 - 81

← 1 2 3 4 5 6 7 →